New Hope for Lupus Nephritis: FDA-Approved Medications Explained

By Dr. Robert Katz

Food and Drug Administration (FDA) has approved several therapies specifically for lupus nephritis (LN). These drugs have been studied in clinical trials and shown to help protect kidney function and reduce inflammation.

When lupus affects the kidneys, it’s called lupus nephritis (LN), a condition that can be life-threatening without effective treatment. Fortunately, the U.S.

There are three FDA approved drugs to treat LN and more are being studied. Here’s information on the three currently approved for LN. LN can be unpredictable and serious, and not all patients respond well to older treatments.

Approved drugs like Benlysta, Lupkynis, and now Gazyva provide more options tailored to controlling the immune attacks that damage the kidneys.

Benlysta (belimumab)
Benlysta is a biologic drug that blocks B cells and helps calm the immune system. Benlysta is given by intravenous infusion or weekly injection. Benlysta is given in addition to standard lupus therapies like steroids and mycophenolate.

Lupkynis (voclosporin)
Lupkynis is an oral immunosuppressant and helps suppress an over active immune system. Lupkynis was the first FDA approved oral medicine specifically for lupus nephritis. Lupkynis is taken daily with standard lupus therapies.

Gazyva (obinutuzumab)
Gazyva is a monoclonal antibody that targets immune cells. Gazyva is the newest LN drug and has strong evidence of improving kidney outcomes. Gazyva is given by infusion, typically a series of doses in the first year followed by maintenance dosing every six months. Gazyva is given in addition to standard lupus therapies.

Research continues for new and better LN treatments.

Scientists continue to study new medications and combinations to improve outcomes even further. Each new approval builds on years of clinical research and offers hope to people living with lupus nephritis.